孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘疗效和安全性的Meta分析

Therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma: a Meta analysis

摘要:

目的 评价孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘的疗效和安全性。方法 计算机检索中国知网、万方、维普、PubMed、EMbase、BioMedCenral数据库等，纳入孟鲁司特钠联合布地奈德治疗儿童咳嗽变异性哮喘的随机对照试验，对符合纳入标准的临床研究进行资料提取和质量评价，采用RevMan5.3软件对纳入文献进行质量评价和Meta分析。结果 共纳入11篇中文文献，合计受试者1097例。Meta分析结果显示：观察组 （孟鲁司特钠联合布地奈德吸入）的总有效率及肺功能指标第一秒用力呼气容积 （FEV₁）、第一秒用力呼气容积百分比 （FEV₁%）、呼气流量峰值 （PEF）明显高于对照组 （单用布地奈德吸入） （P < 0.01）；观察组的复发率明显低于对照组 （P < 0.01）；不良反应发生率两组比较差异无统计学意义。结论 孟鲁司特钠联合布地奈德吸入治疗儿童咳嗽变异性哮喘临床治疗效果明显，且不增加不良反应的发生。

Abstract:

Objective To evaluate the therapeutic effect and safety of montelukast sodium combined with budesonide in children with cough variant asthma. Methods The databases CNKI, Wanfang Data, VIP, PubMed, EMbase, and BioMed Central were searched for randomized controlled trials (RCTs) of montelukast sodium combined with budesonide in the treatment of children with cough variant asthma. Data extraction and quality assessment were performed for RCTs which met the inclusion criteria, and RevMan 5.3 software was used to perform quality assessment of the articles included and Meta analysis. Results A total of 11 RCTs involving 1 097 patients were included. The results of the Meta analysis showed that compared with the control group (inhalation of budesonide alone), the observation group (inhalation of montelukast sodium combined with budesonide) had significantly higher overall response rate and more improved pulmonary function parameters including forced expiratory volume in the first second, percentage of forced expiratory volume in the first second, and peak expiratory flow, as well as significantly lower recurrence rate (P < 0.01). The incidence of adverse events showed no significant difference between the two groups. Conclusions Inhalation of montelukast sodium combined with budesonide has a significant effect in children with cough variant asthma and does not increase the incidence of adverse events.